BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qvigstad G, Waldum H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol. 2004;94:202-208. [PMID: 15125689 DOI: 10.1111/j.1742-7843.2004.pto940502.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Krznaric Z, Ljubas Kelecic D, Rustemovic N, Vranesic Bender D, Ostojic R, Markos P, Scarpignato C. Pharmaceutical principles of acid inhibitors: unmet needs. Dig Dis 2011;29:469-75. [PMID: 22095012 DOI: 10.1159/000331515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Cui G, Waldum HL. Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 2007; 13(4): 493-496 [PMID: 17278212 DOI: 10.3748/wjg.v13.i4.493] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
3 Severi JA, Lima ZP, Kushima H, Brito AR, Santos LC, Vilegas W, Hiruma-Lima CA. Polyphenols with antiulcerogenic action from aqueous decoction of mango leaves (Mangifera indica L.). Molecules 2009;14:1098-110. [PMID: 19305363 DOI: 10.3390/molecules14031098] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
4 Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O'Donnell L, Hilmer SN. A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf 2018;17:39-49. [PMID: 29072544 DOI: 10.1080/14740338.2018.1397625] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
5 Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19. [PMID: 16433886 DOI: 10.1111/j.1742-7843.2006.pto_378.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 6.0] [Reference Citation Analysis]
6 Safer DJ. Overprescribed Medications for US Adults: Four Major Examples. J Clin Med Res 2019;11:617-22. [PMID: 31523334 DOI: 10.14740/jocmr3906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21:149-154. [PMID: 15679764 DOI: 10.1111/j.1365-2036.2004.02271.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
8 Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol 2007;7:583-92. [PMID: 17997137 DOI: 10.1016/j.coph.2007.09.011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
9 Chien LN, Huang YJ, Shao YH, Chang CJ, Chuang MT, Chiou HY, Yen Y. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. Int J Cancer. 2016;138:1401-1409. [PMID: 26488896 DOI: 10.1002/ijc.29896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009;44:564-70. [PMID: 19263272 DOI: 10.1080/00365520902745062] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
11 Pasina L, Novella A, Elli C, Nobili A, Ianes A. Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study. Pharmacoepidemiol Drug Saf 2020;29:461-6. [DOI: 10.1002/pds.4963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Black JW. Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer. Eur J Cancer 2009;45:360-4. [PMID: 19131241 DOI: 10.1016/j.ejca.2008.11.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Pasina L, Urru SAM, Mandelli S, Giua C, Minghetti P; SGCP Investigators. Evidence-based and unlicensed indications for proton pump inhibitors and patients’ preferences for discontinuation: a pilot study in a sample of Italian community pharmacies. J Clin Pharm Ther 2016;41:220-3. [DOI: 10.1111/jcpt.12371] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
14 Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scandinavian Journal of Gastroenterology 2010;45:389-94. [DOI: 10.3109/00365520903477348] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
15 Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 2009;11:433-41. [PMID: 19903418 DOI: 10.1007/s11894-009-0067-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
16 Mordecai A, Sellon RK, Mealey KL. Normal dogs treated with famotidine for 14 days have only transient increases in serum gastrin concentrations. J Vet Intern Med 2011;25:1248-52. [PMID: 22092612 DOI: 10.1111/j.1939-1676.2011.00826.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bamford M. 3 H+/K+ ATPase Inhibitors in the Treatment of Acid-Related Disorders. Progress in Medicinal Chemistry Volume 47. Elsevier; 2009. pp. 75-162. [DOI: 10.1016/s0079-6468(08)00203-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
18 Opar A. A close look at acid reflux drugs points to possible risks. Nat Med 2009;15:710. [PMID: 19584839 DOI: 10.1038/nm0709-710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]